Clinical Trial Update: A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) [Phase 2]

View source ↗

Summary

Phase 2 trial (TAI-SHAN11) of DZD8586 in adults with primary immune thrombocytopenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• DZD8586

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Immune Thrombocytopenia (ITP) | Phase 2 | Status: RECRUITING